Drugs / Sabestomig
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05216835 | Mar 2022 → Aug 2024 | classic Hodgkin lymphoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04612751 | Feb 2021 → May 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04931654 | Sep 2021 → Dec 2024 overdue | gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabestomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04541108 ↗ |
| Known as | AZD7789 | “Sabestomig (AZD7789)” NCT05216835 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314771 ↗ |
| Route | Intravenous | “AZD7789 administered intravenously (IV)” NCT04931654 ↗ |